Participants, investigators and ethics committees will all ask what happens when a trial ends, and the answer should exist before the first participant enrolls. Post-trial access planning means deciding in advance whether, how and for whom continued access to the investigational product will be provided, how continuity of care will be handled and how this will be explained during informed consent. Sponsors who leave it until the last visit face hard choices under pressure.
Why plan before the trial starts?
Ethical guidance expects it. The Declaration of Helsinki calls for post-trial provisions to be arranged in advance of a trial and disclosed to participants during informed consent. Ethics committees and regulators in many countries ask about it at submission. And practically, the options for continued access, such as an extension study or an expanded access program, take time to set up, budget for and staff.
What are the options?
Open-label extension studies, which continue treatment while collecting longer-term data.
Expanded access or compassionate use programs, subject to each country's rules.
Rollover protocols that move participants from several studies into one continuing study.
Transition to approved therapy or standard care, with support for continuity.
No continued access, with a clear explanation of why, where the benefit-risk or development status does not support it.
Which questions should the plan answer?
Who will be eligible for continued access, and on what criteria? How will benefit and safety be assessed? How long will access last, and what would end it? Who will supply, pay for and oversee the product? How will safety data continue to be collected? What happens in countries where the product will not be developed further? And how will all of this be explained to participants?
Why is it especially important in rare and serious diseases?
When participants have few or no alternatives, stopping an apparently beneficial treatment at the end of a study can cause real harm and erode trust in the community. Patient advocacy groups will want to know the sponsor's intentions early. A thoughtful, honest plan, even one with limits, builds credibility.
What are the budget and supply implications?
Continued access requires drug supply, manufacturing capacity, site and CRO support, safety reporting and sometimes regulatory submissions for years. Small sponsors should include these costs in their financing plans and partnering discussions, rather than discovering them when the study ends.
How should it be communicated?
In the informed consent form, in plain language, without promising what the sponsor cannot guarantee. Make sure investigators understand the plan so they can answer participants' questions consistently. If the plan changes, communicate promptly and honestly with sites, participants and ethics committees.
What if the program fails or is paused?
Plan for that too. Decide how participants will transition safely, how investigators will be supported and how results will be shared. A sponsor's conduct when a program ends is often what the community remembers most.
Keep reading: Partnering With Patient Advocacy Groups in Rare Disease Trials
